# Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults

> **NCT06669234** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 56 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** ALN-F1202
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT06669234
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-06
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-07-30
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06669234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06669234, "Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06669234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*